Zai Lab (ZLAB) announced the appointment of Rafael Amado, M.D. as President, Head of Global Oncology Research and Development, R&D, effective December 30, 2022. Dr. Amado will report to Dr. Du and will be a key member of the Company’s executive committee. He will be responsible for leading and overseeing the Company’s global oncology research and development activities. Dr. Amado joins Zai Lab from Allogene Therapeutics (ALLO), where he has served as Executive Vice President, Head of Research and Development and Chief Medical Officer since September 2019.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZLAB:
- Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development
- Zai Lab Announces Participation in January Investor Conferences
- Zai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary
- Zai Lab presents new interim OS data from NORA study
- Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)